Loading...
RUNX1 dosage in development and cancer
Lie-A-Ling, Michael Mevel, Renaud Patel, Rahima Blyth, K Baena, Esther Kouskoff, V Lacaud, Georges
Lie-A-Ling, Michael
Mevel, Renaud
Patel, Rahima
Blyth, K
Baena, Esther
Kouskoff, V
Lacaud, Georges
Citations
Altmetric:
Abstract
The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.
Description
Date
2020
Publisher
Collections
Files
Loading...
molce-43-126.pdf
Adobe PDF, 734.3 KB
Keywords
Type
Article
Citation
Lie-a-ling M, Mevel R, Patel R, Blyth K, Baena E, Kouskoff V, et al. RUNX1 Dosage in Development and Cancer. Mol Cells. 2020;43(2):126-38.